Abstract
Overview
Introduction
Stimulated by sales of atypical antipsychotics for bipolar depression, and
despite the launch of generic risperidone, the global bipolar disorder market
will grow until 2011, when revenues will peak at $6.6 billion. The market will
begin to decline thereafter owing to the launch of generic versions of the
leading atypical antipsychotics, quetiapine, olanzapine, and ziprasidone from
2011 onwards.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
bipolar disorder
- Overview of drugs in pre-registration, Phase III, II and I; with analysis
of key companies involved in the market
- Detailed profiles of key compounds in development for use in bipolar
disorder, with forecasts of drug revenues to 2015
- Discussion of indication expansion strategies and insight from key
industry opinion leaders
Highlights
AstraZeneca will be the first company to bring an atypical antipsychotic to
the bipolar depression market as a monotherapy, following demonstration of
efficacy with quetiapine. Pfizer will maintain a strong schizophrenia
franchise by releasing asenapine to buffer the loss in revenue due to
genericization of ziprasidone.
Solvay/Wyeth/Lundbeck's bifeprunox will be the leading market entrant in terms
of bipolar disorder specific sales revenue. These companies appear to be
seeking initial license for bifeprunox in the bipolar depression indication, a
tactic that will both increase the commercial viability of the drug and save
time/money.
Despite the commercial success of Lamictal (lamotrigine) and Depakote
(valproate), the late-stage bipolar disorder pipeline only includes one
anticonvulsant class molecule, Novartis' licarbazepine.
Reasons to Purchase
- Understand unmet needs in the bipolar disorder market based on key opinion
leader comments
- Benchmark key late-stage bipolar disorder compounds against current market
leaders
- Assess the global (US, Japan, five major EU) sales forecasts of late-stage
pipeline drugs; and examine their clinical and commercial potential
| 
View Cart
